Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF) CEO Wayne Paterson will present at the Cantor Fitzgerald Annual Global Healthcare Conference in New York, NY on Tuesday, September 26, 2023, at 2:45 pm Eastern Time.
Paterson is set to unveil recent clinical data on DurAVR™, the firm's flagship Transcatheter Aortic Valve Replacement (TAVR) technology for addressing aortic stenosis.
Subsequent to the data presentation, a dialogue with Cantor's medical technology analyst, Ross Osborn, will take place in the format of a fireside chat.
The conference will also offer opportunities for one-on-one meetings with investors. Institutional investors looking to arrange a meeting can reach out to Cantor's sales team or their Corporate Access division at corporateaccess@cantor.com.
Changing the game
Anteris is a structural heart company developing the world’s only balloon-expandable, single-piece transcatheter aortic valve (TAVR) for the treatment of aortic stenosis.
DurAVR™ THV continues to be investigated in a clinical trial setting for severe aortic stenosis patients in two Early Feasibility Studies (EFS) being conducted in the US (ClinicalTrials.gov NCT05712161) and Europe (Clinicaltrials.gov NCT05182307).
One-year data from European EFS of DurAVRTM was presented at the TVT structural Heart Conference on June 9, 2023, and is available on the investor portal of the Anteris website.
Thirty-day data results from the ongoing US EFS of DurAVR™ is targeted for the fourth quarter of this year.